Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder that leads to memory loss and a severe decline in cognitive abilities, significantly interfering with daily life. Tens of millions of people are living with cognitive symptoms of AD, and hundreds of millions more may have tau and amyloid pathology—the hallmark proteins associated with the disease—starting to accumulate in their brains potentially decades before clinical signs emerge.
As symptoms progress, AD imposes a significant burden on patients, caregivers, health systems and society. It is among the top 10 leading causes of death globally, with its economic toll projected to reach nearly $3 trillion by 2030.
Alzheimer’s disease is among the top 10 leading causes of death globally, with its economic toll projected to reach nearly $3 trillion by 2030.
J&J’s approach to Alzheimer’s disease
For decades, we’ve been committed to researching and developing potential treatments for Alzheimer’s disease. Guided by a legacy of innovation and scientific progress, we continue to deepen our understanding of the disease and progress tools that may enable earlier, more targeted intervention. Today, we’re applying this knowledge to advance the next generation of Alzheimer’s therapies – both symptomatic and disease-modifying – to support patients across the spectrum of disease.
We’re also exploring tools to identify and diagnose the disease earlier and more definitively, recognizing that detecting disease pathology before symptoms appear is essential to changing the course of the disease.
